. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: Mult Scler. 2020 Jul 7;27(6):942–953. doi: 10.1177/1352458520936226

Table 3.

Change in fatigue and key MS symptoms severity

	Randomization group		P-value for the difference in the rate of change
	Midazolam	Ketamine
Change in daily fatigue severity, points/day (95% CI)^*	−0.05 (−0.14, 0.24)	−0.05 (−0.19, 0.08)	0.40

Change in secondary outcomes, points/day (95% CI)
FSS	0.19 (−0.88, 1.26)	−0.74 (−1.49, 0.02)	0.06
Neuro-QoL fatigue T-score	−0.46 (−1.20, 0.27)	−1.02 (−1.54, −0.50)	0.24
MFIS total	0.02 (−0.35, 0.32)	−0.46 (−0.23, − 0.70)	0.04
MFIS physical	0.04 (−0.12, 0.19)	−0.20 (−0.31, −0.09)	0.03
MFIS cognitive	0.00 (−0.16, 0.16)	−0.22 (−0.24, 0.11)	0.05
MFIS psychosocial	0.02 (−0.07, 0.03)	−0.04 (−0.07, 0.00)	0.52
Change in other MS symptoms, points/day (95% CI)
BDI	0.07 (−0.33, 0.18)	0.07 (−0.25, 0.11)	1.00
ESS	0.11 (−0.11, 0.32)	0.03 (−0.18, 0.12)	0.32

FSS: fatigue severity scale; MFIS: modified fatigue impact scale; BDI: Beck depression inventory, ESS: Epworth sleepiness scale.

Rates of change are derived from mixed effects models.